Equities Analysts Issue Forecasts for Sernova Q3 Earnings

Sernova Corp. (TSE:SVA) – Equities researchers at HC Wainwright issued their Q3 2026 earnings estimates for shares of Sernova in a research report issued on Tuesday, September 8th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share. HC Wainwright also issued estimates for Sernova’s Q4 2026 earnings at ($0.01) EPS.

Sernova (TSE:SVA) last posted its earnings results on Thursday, June 11th. The company reported C$0.01 EPS for the quarter.

Sernova Stock Up 7.7%

Shares of Sernova stock opened at C$0.14 on Thursday. Sernova has a 12-month low of C$0.10 and a 12-month high of C$0.20. The company has a quick ratio of 18.11, a current ratio of 0.14 and a debt-to-equity ratio of -25.45. The stock has a 50 day moving average price of C$0.11 and a two-hundred day moving average price of C$0.14. The stock has a market capitalization of C$52.87 million, a P/E ratio of -3.50 and a beta of -0.43.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.